Company intelligence / Profile preview

Celea Therapeutics

Boston, Massachusetts, United States

Ownership: Private
Development stage: Other

Overview

Celea Therapeutics is advancing deupirfenidone (LYT-100), a deuterated small molecule analog of pirfenidone, for idiopathic pulmonary fibrosis (IPF). In a Phase 2b trial, deupirfenidone demonstrated a statistically significant reduction in lung function decline versus placebo and pirfenidone at 26 weeks, with a favourable safety and tolerability profile. Open-label extension data show maintained efficacy and safety over 52 weeks. Celea is preparing for Phase 3 trials as of late 2025.

Therapeutic areas: Pulmonology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Celea Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Celea Therapeutics.

Explore the full profile